공지 • Apr 22
ACI Formulations PLC to Report Q3, 2026 Results on Apr 29, 2026 ACI Formulations PLC announced that they will report Q3, 2026 results on Apr 29, 2026 공지 • Jan 21
ACI Formulations PLC to Report Q2, 2026 Results on Jan 29, 2026 ACI Formulations PLC announced that they will report Q2, 2026 results on Jan 29, 2026 공지 • Nov 10
ACI Formulations PLC to Report Q1, 2026 Results on Nov 12, 2025 ACI Formulations PLC announced that they will report Q1, 2026 results on Nov 12, 2025 공지 • Oct 30
ACI Formulations PLC announces Annual dividend, payable on January 27, 2026 ACI Formulations PLC announced Annual dividend of BDT 2.5000 per share payable on January 27, 2026, ex-date on November 20, 2025 and record date on November 19, 2025. 공지 • Oct 29
ACI Formulations PLC, Annual General Meeting, Dec 28, 2025 ACI Formulations PLC, Annual General Meeting, Dec 28, 2025, at 10:00 Central Asia Standard Time. 공지 • Oct 21
ACI Formulations PLC to Report Fiscal Year 2025 Results on Oct 28, 2025 ACI Formulations PLC announced that they will report fiscal year 2025 results on Oct 28, 2025 공지 • Apr 21
ACI Formulations Limited to Report Q3, 2025 Results on Apr 29, 2025 ACI Formulations Limited announced that they will report Q3, 2025 results on Apr 29, 2025 공지 • Jan 22
ACI Formulations Limited to Report Q2, 2025 Results on Jan 30, 2025 ACI Formulations Limited announced that they will report Q2, 2025 results on Jan 30, 2025 New Risk • Nov 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (93% net debt to equity). Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (৳5.68b market cap, or US$47.3m). Upcoming Dividend • Nov 14
Upcoming dividend of ৳2.00 per share Eligible shareholders must have bought the stock before 18 November 2024. Payment date: 28 January 2025. Payout ratio is a comfortable 42% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of Bangladeshi dividend payers (4.5%). Lower than average of industry peers (7.4%). 공지 • Nov 11
ACI Formulations Limited to Report Q1, 2025 Results on Nov 14, 2024 ACI Formulations Limited announced that they will report Q1, 2025 results on Nov 14, 2024 Declared Dividend • Oct 31
Dividend of ৳2.00 announced Shareholders will receive a dividend of ৳2.00. Ex-date: 18th November 2024 Payment date: 28th January 2025 Dividend yield will be 1.7%, which is lower than the industry average of 2.0%. Sustainability & Growth Dividend is well covered by both earnings (42% earnings payout ratio) and cash flows (15% cash payout ratio). The dividend has increased over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 17% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. 공지 • Oct 21
ACI Formulations Limited to Report Fiscal Year 2024 Results on Oct 28, 2024 ACI Formulations Limited announced that they will report fiscal year 2024 results on Oct 28, 2024 Reported Earnings • May 02
Third quarter 2024 earnings released: EPS: ৳2.04 (vs ৳1.33 in 3Q 2023) Third quarter 2024 results: EPS: ৳2.04 (up from ৳1.33 in 3Q 2023). Revenue: ৳1.23b (down 5.7% from 3Q 2023). Net income: ৳96.4m (up 54% from 3Q 2023). Profit margin: 7.8% (up from 4.8% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 6% per year. 공지 • Apr 26
ACI Formulations Limited to Report Q3, 2024 Results on Apr 29, 2024 ACI Formulations Limited announced that they will report Q3, 2024 results on Apr 29, 2024 Reported Earnings • Feb 18
Second quarter 2024 earnings released: EPS: ৳2.70 (vs ৳2.49 in 2Q 2023) Second quarter 2024 results: EPS: ৳2.70 (up from ৳2.49 in 2Q 2023). Revenue: ৳1.39b (down 3.3% from 2Q 2023). Net income: ৳127.6m (up 8.6% from 2Q 2023). Profit margin: 9.2% (up from 8.2% in 2Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 9% per year. 공지 • Jan 23
ACI Formulations Limited to Report Q2, 2024 Results on Jan 30, 2024 ACI Formulations Limited announced that they will report Q2, 2024 results on Jan 30, 2024 Upcoming Dividend • Nov 12
Upcoming dividend of ৳2.50 per share at 1.6% yield Eligible shareholders must have bought the stock before 19 November 2023. Payment date: 28 January 2024. Payout ratio is a comfortable 47% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of Bangladeshi dividend payers (3.3%). Lower than average of industry peers (2.2%). 공지 • Oct 20
ACI Formulations Limited to Report Fiscal Year 2023 Results on Oct 26, 2023 ACI Formulations Limited announced that they will report fiscal year 2023 results on Oct 26, 2023 공지 • Jun 12
ACI Formulations Limited Announces Executive Changes ACI Formulations Limited has informed that the Board of Directors approved the resignation of the previous company secretary, Mr. Nayamul Hoque. The Board also decided that Mr. Mohammad Mostafizur Rahman will be the acting Company Secretary of the company until the new Company Secretary is appointed to this position. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Golam Mainuddin was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공지 • Oct 28
ACI Formulations Limited Recommends Cash Dividend for the Year Ended June 30, 2022 ACI Formulations Limited has recommended 25% cash dividend for the year ended June 30, 2022. Reported Earnings • May 28
Third quarter 2022 earnings released: EPS: ৳1.53 (vs ৳1.48 in 3Q 2021) Third quarter 2022 results: EPS: ৳1.53 (up from ৳1.48 in 3Q 2021). Revenue: ৳1.16b (up 5.0% from 3Q 2021). Net income: ৳72.1m (up 2.8% from 3Q 2021). Profit margin: 6.2% (down from 6.4% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 25
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ৳161, the stock trades at a trailing P/E ratio of 27.5x. Average trailing P/E is 28x in the Chemicals industry in Bangladesh. Total returns to shareholders of 27% over the past three years. Valuation Update With 7 Day Price Move • May 10
Investor sentiment improved over the past week After last week's 23% share price gain to ৳205, the stock trades at a trailing P/E ratio of 34.9x. Average trailing P/E is 32x in the Chemicals industry in Bangladesh. Total returns to shareholders of 55% over the past three years. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Golam Mainuddin was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 06
Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations Second quarter 2022 results: EPS: ৳2.59 (up from ৳1.96 in 2Q 2021). Revenue: ৳1.27b (up 19% from 2Q 2021). Net income: ৳122.5m (up 32% from 2Q 2021). Profit margin: 9.6% (in line with 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jan 22
Investor sentiment improved over the past week After last week's 15% share price gain to ৳179, the stock trades at a trailing P/E ratio of 34.2x. Average trailing P/E is 34x in the Chemicals industry in Bangladesh. Total returns to shareholders of 24% over the past three years. Upcoming Dividend • Nov 14
Upcoming dividend of ৳3.00 per share Eligible shareholders must have bought the stock before 21 November 2021. Payment date: 25 January 2022. Trailing yield: 1.9%. Lower than top quartile of Bangladeshi dividend payers (3.0%). In line with average of industry peers (2.0%). Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment improved over the past week After last week's 17% share price gain to ৳190, the stock trades at a trailing P/E ratio of 44.5x. Average trailing P/E is 40x in the Chemicals industry in Bangladesh. Total returns to shareholders of 27% over the past three years. Is New 90 Day High Low • Feb 23
New 90-day low: ৳113 The company is down 5.0% from its price of ৳119 on 25 November 2020. The Bangladeshi market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 9.0% over the same period. Is New 90 Day High Low • Jan 11
New 90-day high: ৳126 The company is up 9.0% from its price of ৳116 on 13 October 2020. The Bangladeshi market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 6.0% over the same period. Is New 90 Day High Low • Nov 02
New 90-day low: ৳111 The company is down 12% from its price of ৳127 on 04 August 2020. The Bangladeshi market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is flat over the same period.